The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Advice for community physicians on the management of mantle cell lymphoma
Julie Vose, MD, University of Nebraska Medical Center, Omaha, NE, discusses steps that should be taken by community physicians when managing a patient with mantle cell lymphoma (MCL). She recommends a thorough hematopathology review to determine the disease stage and subtype, testing for TP53 mutations, and considering clinical trial enrollment. Prof. Vose also mentions trial results indicating that bendamustine plus rituximab for initial therapy, followed by rituximab maintenance, could be a promising regimen for standard-risk patients. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
